

Equivalent of Form PTO/SB/08A (07-05)

Approved for use through 07/31/2006

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO					<div>Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.</div> <div>Complete if Known</div>	
<div>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</div> <div><i>(Use as many sheets as necessary)</i></div>					Application Number	10/596,945
					Filing Date	December 14, 2004
					First Named Inventor	Susumu SHIOMI
					Art Unit	To be assigned
					Examiner Name	To be assigned /Phyllis Spivack/
					Attorney Docket Number	1089.0600000/MAC/DJN
Sheet	1	of	1			

[illegible]

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ Number ⁴ Kind Code ⁵ (if known)				
	FP1	JP 49-55650	05/30/1974	Eisai Co., Ltd.		
	FP2	JP 63-185924	08/01/1988	Takeda Chem. Ind. Ltd.		Abs
	FP3	JP 08-305955	11/01/1994	Eisai Co., Ltd.		Abs
	FP4	WO 03/105819 A1	12/24/2003	Eisai Co., Ltd.		Abs

550049v1

Examiner Signature	/Phyllis Spivack/	Date Considered	02/29/2008
-----------------------	-------------------	--------------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. **SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.S./

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/596,945
				Filing Date	December 14, 2004
				First Named Inventor	Susumu SHIOMI
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	1	of	3	Attorney Docket Number	1089.0600000/MAC/DJN

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume issue number(s), publisher, city and/or country where published	T ²
	NPL1	Furukawa, M., <i>et al.</i> , "Changes of Plasma Des-γ-Carboxy Prothrombin Levels in Patients With Hepatocellular Carcinoma in Response to Vitamin K," <i>Cancer</i> 69:31-38, J.B. Lippincott Company (1992)	
	NPL2	Habu, D., <i>et al.</i> , "Role of Vitamin K ₂ in the Development of Hepatocellular Carcinoma in Women With Viral Cirrhosis of the Liver," <i>JAMA</i> 292:358-361, American Medical Association (July 2004)	
	NPL3	Ichida, F., <i>et al.</i> , "Clinical evaluation of human lymphoblastoid interferon (OPC-18) in patients with inactive chronic hepatitis C - A randomization study to find the optimal duration of treatment," <i>Kantansui</i> 32:101-127, ArcMedium (1996)	
	NPL4	Ikeda, K. and Kumada, H., "Clinical significance of long-term natural course of and treatment of chronic hepatitis C liver disease," <i>Kanzo</i> 35:772-773, Nihon Kanzo Gakkai (1994)	
	NPL5	Johnson, J.I., <i>et al.</i> , "Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials," <i>Brit. J. Canc.</i> 84:1424-1431, Nature Publishing Group on behalf of Cancer Research UK (2001)	
	NPL6	Koike, Y., <i>et al.</i> , "Des-γ-Carboxy Prothrombin As a Useful Predisposing Factor for the Development of Portal Venous Invasion in Patients with Hepatocellular Carcinoma," <i>Cancer</i> 91:561-569, John Wiley & Sons, Inc. (2001)	
	NPL7	Koike, Y., <i>et al.</i> , "Randomized Prospective Study of Prevention from Tumor Invasion into Portal Vein in 120 Patients with Hepatocellular Carcinoma by Vitamin K Administration," available online at http://ddw02.agora.com/planner/displayabstract.asp?presentationid=31 , Abstract ID 105864, 1 page (2002)	
	NPL8	Koike, Y., <i>et al.</i> , "A Randomized Prospective Controlled Study by Vitamin K-II Injection for the Purpose of Preventing Portal Venous Invasion (PVI)," <i>Kanzo</i> 43(suppl.1):A64, abstract no. O-98, Nihon Kanzo Gakkai (2002)	Yes
	NPL9	Unverified English language translation of Koike, Y., <i>et al.</i> , "A Randomized Prospective Controlled Study by Vitamin K-II Injection for the Purpose of Preventing Portal Venous Invasion (PVI)," <i>Kanzo</i> 43(suppl.1):A64, abstract no. O-98, Nihon Kanzo Gakkai (2002)	

550251v1

Examiner Signature	/Phyllis Spivack/	Date Considered	02/29/2008
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.S./

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/596,945
				Filing Date	December 14, 2004
				First Named Inventor	Susumu SHIOMI
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	2	of	3	Attorney Docket Number	1089.0600000/MAC/DJN

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL10	Li, Z.-Q., <i>et al.</i> , "Vitamin K uptake in hepatocytes and hepatoma cells," <i>Life Sci.</i> 70:2085-2100, Elsevier Science Inc. (2002)	
	NPL11	Mizuta, T., <i>et al.</i> , "A Clinical Study of the Effects of Vitamin K in Inhibiting Recurrence of Hepatocellular Carcinoma," <i>Jpn. J. Gastroenterol.</i> 99:A192, abstract no. 308, Gastroenterological Association of Japan (2002)	Yes
	NPL12	Unverified English language translation of Mizuta, T., <i>et al.</i> , "A Clinical Study of the Effects of Vitamin K in Inhibiting Recurrence of Hepatocellular Carcinoma," <i>Jpn. J. Gastroenterol.</i> 99:A192, abstract no. 308, Gastroenterological Association of Japan (2002)	
	NPL13	Mizuta, T., <i>et al.</i> , "Inhibitory effect of vitamin K injection against the recurrence of hepatocellular carcinoma," <i>38th Annual Meeting of Liver Cancer Study Group of Japan</i> , pg. 135, abstract no. 110, (2002)	Yes
	NPL14	Unverified English language translation of Mizuta, T., <i>et al.</i> , "Inhibitory effect of vitamin K injection against the recurrence of hepatocellular carcinoma," <i>38th Annual Meeting of Liver Cancer Study Group of Japan</i> , pg. 135, abstract no. 110, (2002)	
	NPL15	Mizuta, T. and Yamamoto, K., "Vitamin K2 agent to inhibit recurrence of hepatic cancer," <i>J. Ther.</i> 89:1554-1555, Tokyo (April 2003)	
	NPL16	Nishiguchi, S., <i>et al.</i> , "Randomised trial of effects of interferon- α on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis," <i>Lancet</i> 346:1051-1055, Lancet Publishing Group (1995)	
	NPL17	Ohizumi, H., <i>et al.</i> , "Geranylgeraniol Is a Potent Inducer of Apoptosis in Tumor Cells," <i>J. Biochem.</i> 117:11-13, Oxford University Press (1995)	
	NPL18	O'Neil, J.M., <i>et al.</i> , eds., "Vitamin K," in: <i>The Merck Index</i> , 13 th Ed., Merck & Co., Inc., Rahway, NJ, page 1787, item 10082, (2001)	
	NPL19	Wang, Z., <i>et al.</i> , "The Growth Inhibitory Effects of Vitamins K and Their Actions on Gene Expression," <i>Hepatol.</i> 22:876-882, John Wiley & Sons, Inc. (1995)	

Examiner Signature	/Phyllis Spivack/	Date Considered	02/29/2008
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.S./

PTO/SB/08B (07-05)

Approved for use through 07/31/2006. OMB 0651-0031
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)				Application Number	10/596,945
				Filing Date	December 14, 2004
				First Named Inventor	Susumu SHIOMI
				Art Unit	To be assigned
				Examiner Name	To be assigned
Sheet	3	of	3	Attorney Docket Number	1089.0600000/MAC/DJN

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume number, publisher, city and/or country where published	T ²
	NPL20	Wu, F.Y.-H., <i>et al.</i> , "Comparison of Antitumor Activity of Vitamins K ₁ , K ₂ , and K ₃ on Human Tumor Cells by Two (MTT and SRB) Cell Viability Assays," <i>Life Sci.</i> 52:1797-1804, Pergamon Press (1993)	
	NPL21	Yamaoka, Y., <i>et al.</i> , Liver Cancer Study Group of Japan, "Survey and Follow-up study of primary liver cancer in Japan, Report 14," <i>Kanzo</i> 41:799-810, Nihon Kanzo Gakkai (2000)	Abs
	NPL22	English language abstract of Yamaoka, Y., <i>et al.</i> , Liver Cancer Study Group of Japan, "Survey and Follow-up study of primary liver cancer in Japan, Report 14," <i>Kanzo</i> 41:799-810, Nihon Kanzo Gakkai (2000)	
	NPL23	STN Database, Registry No. 863-61-6, "1,4-Naphthalenedione, 2-methyl-3-[(2E,6E,10E)-3,7,11,15-tetramethyl-2,6,10,14-hexadecatetraenyl]" (1984)	
	NPL24	Copy of Russian Official Action for Russian Application No. 2004136304/15(039482), Russian Patent and Trademark Office, dated March 29, 2006	Yes
	NPL25	Unverified English language translation of Russian Official Action for Russian Application No. 2004136304/15(039482), Russian Patent and Trademark Office, dated March 29, 2006	
	NPL26	Patent Abstracts of Japan, English language abstract for JP 63-185921 (1988) .	
	NPL27	Patent Abstracts of Japan, English language abstract for JP 06-305955 (1994) .	
	NPL28	Dialog File 351, Accession No. 15924220, WPI English language abstract of WO 03/105819 (listed on accompanying PTO/SB/08A as document FP4) (2003) .	
	NPL29	Copy of International Search Report for International Patent Application No. PCT/JP2004/018643, mailed April 19, 2005, Japanese Patent Office, Japan	

550251v1

Examiner Signature	/Phyllis Spivack/	Date Considered	02/29/2008
--------------------	-------------------	-----------------	------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH. /P.S./